Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Blood (2025) 146 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2025-2275

Published: 2025

Journal Articles

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Blood (2025) 146 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2025-5836

Published: 2025

Journal Articles

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Blood (2025) 146 (Supplement 1): 744.

https://doi.org/10.1182/blood-2025-744

Published: 2025

Journal Articles

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Blood (2025) 146 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2025-3883

Published: 2025

Journal Articles

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Blood blood.2025029999.

https://doi.org/10.1182/blood.2025029999

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mourad Tiab, Mohamad Mohty, Frederique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini-Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hebraud, Laurent Flet, Jean-Valere Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cecile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Helene Demarquette, Valentine Richez, Brieuc Cherel, Laurent Frenzel, Marie-Christiane Vekemans, Noemie Bigot, Herve Avet-Loiseau, Jill Corre, Philippe Moreau

Blood (2025) 146 (1): 52–61.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

Thierry Lamy, Cedric Pastoret, Gandhi Damaj, Olivier Tournilhac, Emmanuel Bachy, Loic Ysebaert, Frederique Orsini Piocelle, Anne Banos, Marianne Schwarz, Estibaliz Lazaro, Pierre Feugier, Hugo Gonzalez, Alain Renault, Milena Kohn, Roch Houot, Mikael Roussel, Eric Bellissant

Blood (2024) 144 (Supplement 1): 979.

https://doi.org/10.1182/blood-2024-200266

Published: 2024

Journal Articles

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 774.

https://doi.org/10.1182/blood-2024-203045

Published: 2024

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Blood (2024) 143 (11): 983–995.

https://doi.org/10.1182/blood.2023021564

Published: 2024

Includes: Supplemental data

Journal Articles

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Blood (2023) 142 (Supplement 1): 6742.

https://doi.org/10.1182/blood-2023-185792

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Blood (2023) 141 (11): 1308–1315.

https://doi.org/10.1182/blood.2022017863

Published: 2023

Includes: Supplemental data

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial

Blood (2022) 140 (Supplement 1): 1369–1370.

https://doi.org/10.1182/blood-2022-159933

Published: 2022

Journal Articles

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Blood (2022) 140 (Supplement 1): 4452–4453.

https://doi.org/10.1182/blood-2022-166870

Published: 2022

Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Blood (2022) 140 (Supplement 1): 4423–4425.

https://doi.org/10.1182/blood-2022-168742

Published: 2022

Journal Articles

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Blood (2022) 139 (17): 2666–2672.

https://doi.org/10.1182/blood.2021014968

Published: 2022

Includes: Supplemental data

Journal Articles

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Blood (2021) 138 (Supplement 1): 77.

https://doi.org/10.1182/blood-2021-146869

Published: 2021

Journal Articles

Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma

Blood (2021) 138 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2021-152346

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

RAS/RAF landscape in monoclonal plasma cell conditions

The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Final Analysis of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA) Using Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Patients over 60 Years with Advanced-Stage Classical Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only